3-aminohydantoin derivate as a promising scaffold in dopaminergic neuroprotection and neurorescue in the in vivo and in vitro 6-hydroxydopamine models of Parkinson's disease
Clin Exp Pharmacol Physiol. 2023 Jun 18. doi: 10.1111/1440-1681.13799. Online ahead of print.ABSTRACTParkinson's disease (PD) is a neurodegenerative disorder characterized by a progressive loss of dopaminergic neurons in the substantia nigra, for which no disease-modifying treatments are available yet. Thus, developing new neuroprotective drugs with the potential to delay or stop the natural course of the disease is necessary. The aim of the present study was to evaluate the neuroprotective effects of a newly synthesized 3-aminohydantoin derivative named 3-amino-5-benzylimidazolidine-2,4-dione (PHAH). The possible neuropro...
Source: Clinical and Experimental Pharmacology and Physiology - June 18, 2023 Category: Drugs & Pharmacology Authors: Sahar Mani Houda Bouchnak Sol ène Pradeloux Jamil Kraiem Denis Soulet Imed Messaoudi Source Type: research

3-aminohydantoin derivate as a promising scaffold in dopaminergic neuroprotection and neurorescue in the in vivo and in vitro 6-hydroxydopamine models of Parkinson's disease
Clin Exp Pharmacol Physiol. 2023 Jun 18. doi: 10.1111/1440-1681.13799. Online ahead of print.ABSTRACTParkinson's disease (PD) is a neurodegenerative disorder characterized by a progressive loss of dopaminergic neurons in the substantia nigra, for which no disease-modifying treatments are available yet. Thus, developing new neuroprotective drugs with the potential to delay or stop the natural course of the disease is necessary. The aim of the present study was to evaluate the neuroprotective effects of a newly synthesized 3-aminohydantoin derivative named 3-amino-5-benzylimidazolidine-2,4-dione (PHAH). The possible neuropro...
Source: Clinical and Experimental Pharmacology and Physiology - June 18, 2023 Category: Drugs & Pharmacology Authors: Sahar Mani Houda Bouchnak Sol ène Pradeloux Jamil Kraiem Denis Soulet Imed Messaoudi Source Type: research

3-aminohydantoin derivate as a promising scaffold in dopaminergic neuroprotection and neurorescue in the in vivo and in vitro 6-hydroxydopamine models of Parkinson's disease
Clin Exp Pharmacol Physiol. 2023 Jun 18. doi: 10.1111/1440-1681.13799. Online ahead of print.ABSTRACTParkinson's disease (PD) is a neurodegenerative disorder characterized by a progressive loss of dopaminergic neurons in the substantia nigra, for which no disease-modifying treatments are available yet. Thus, developing new neuroprotective drugs with the potential to delay or stop the natural course of the disease is necessary. The aim of the present study was to evaluate the neuroprotective effects of a newly synthesized 3-aminohydantoin derivative named 3-amino-5-benzylimidazolidine-2,4-dione (PHAH). The possible neuropro...
Source: Clinical and Experimental Pharmacology and Physiology - June 18, 2023 Category: Drugs & Pharmacology Authors: Sahar Mani Houda Bouchnak Sol ène Pradeloux Jamil Kraiem Denis Soulet Imed Messaoudi Source Type: research

3-aminohydantoin derivate as a promising scaffold in dopaminergic neuroprotection and neurorescue in the in vivo and in vitro 6-hydroxydopamine models of Parkinson's disease
Clin Exp Pharmacol Physiol. 2023 Jun 18. doi: 10.1111/1440-1681.13799. Online ahead of print.ABSTRACTParkinson's disease (PD) is a neurodegenerative disorder characterized by a progressive loss of dopaminergic neurons in the substantia nigra, for which no disease-modifying treatments are available yet. Thus, developing new neuroprotective drugs with the potential to delay or stop the natural course of the disease is necessary. The aim of the present study was to evaluate the neuroprotective effects of a newly synthesized 3-aminohydantoin derivative named 3-amino-5-benzylimidazolidine-2,4-dione (PHAH). The possible neuropro...
Source: Clinical and Experimental Pharmacology and Physiology - June 18, 2023 Category: Drugs & Pharmacology Authors: Sahar Mani Houda Bouchnak Sol ène Pradeloux Jamil Kraiem Denis Soulet Imed Messaoudi Source Type: research

3-aminohydantoin derivate as a promising scaffold in dopaminergic neuroprotection and neurorescue in the in vivo and in vitro 6-hydroxydopamine models of Parkinson's disease
Clin Exp Pharmacol Physiol. 2023 Jun 18. doi: 10.1111/1440-1681.13799. Online ahead of print.ABSTRACTParkinson's disease (PD) is a neurodegenerative disorder characterized by a progressive loss of dopaminergic neurons in the substantia nigra, for which no disease-modifying treatments are available yet. Thus, developing new neuroprotective drugs with the potential to delay or stop the natural course of the disease is necessary. The aim of the present study was to evaluate the neuroprotective effects of a newly synthesized 3-aminohydantoin derivative named 3-amino-5-benzylimidazolidine-2,4-dione (PHAH). The possible neuropro...
Source: Clinical and Experimental Pharmacology and Physiology - June 18, 2023 Category: Drugs & Pharmacology Authors: Sahar Mani Houda Bouchnak Sol ène Pradeloux Jamil Kraiem Denis Soulet Imed Messaoudi Source Type: research

3-aminohydantoin derivate as a promising scaffold in dopaminergic neuroprotection and neurorescue in the in vivo and in vitro 6-hydroxydopamine models of Parkinson's disease
Clin Exp Pharmacol Physiol. 2023 Jun 18. doi: 10.1111/1440-1681.13799. Online ahead of print.ABSTRACTParkinson's disease (PD) is a neurodegenerative disorder characterized by a progressive loss of dopaminergic neurons in the substantia nigra, for which no disease-modifying treatments are available yet. Thus, developing new neuroprotective drugs with the potential to delay or stop the natural course of the disease is necessary. The aim of the present study was to evaluate the neuroprotective effects of a newly synthesized 3-aminohydantoin derivative named 3-amino-5-benzylimidazolidine-2,4-dione (PHAH). The possible neuropro...
Source: Clinical and Experimental Pharmacology and Physiology - June 18, 2023 Category: Drugs & Pharmacology Authors: Sahar Mani Houda Bouchnak Sol ène Pradeloux Jamil Kraiem Denis Soulet Imed Messaoudi Source Type: research

Brazilin inhibits bladder cancer by promoting cell necroptosis
In conclusion, the results confirm the involvement of necroptosis in brazilin-induced cell death and suggest that brazilin could be explored as an anticancer agent against bladder cancer.PMID:37321597 | DOI:10.1111/1440-1681.13800 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - June 15, 2023 Category: Drugs & Pharmacology Authors: Xihua Yang Shuaina Zhang Jiao He Lili Zhao Lixia Chen Yongming Yang Jing Wang Lei Yan Tingting Zhang Source Type: research

Brazilin inhibits bladder cancer by promoting cell necroptosis
In conclusion, the results confirm the involvement of necroptosis in brazilin-induced cell death and suggest that brazilin could be explored as an anticancer agent against bladder cancer.PMID:37321597 | DOI:10.1111/1440-1681.13800 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - June 15, 2023 Category: Drugs & Pharmacology Authors: Xihua Yang Shuaina Zhang Jiao He Lili Zhao Lixia Chen Yongming Yang Jing Wang Lei Yan Tingting Zhang Source Type: research

Brazilin inhibits bladder cancer by promoting cell necroptosis
In conclusion, the results confirm the involvement of necroptosis in brazilin-induced cell death and suggest that brazilin could be explored as an anticancer agent against bladder cancer.PMID:37321597 | DOI:10.1111/1440-1681.13800 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - June 15, 2023 Category: Drugs & Pharmacology Authors: Xihua Yang Shuaina Zhang Jiao He Lili Zhao Lixia Chen Yongming Yang Jing Wang Lei Yan Tingting Zhang Source Type: research

Effect of renal denervation on cardiac remodelling and function in rats with chronic intermittent hypoxia
Clin Exp Pharmacol Physiol. 2023 Jun 13. doi: 10.1111/1440-1681.13797. Online ahead of print.ABSTRACTChronic intermittent hypoxia (CIH) mimicking obstructive sleep apnea elicits divergent outcomes in the cardiovascular systems. The effect of renal denervation (RDN) on the heart during CIH remains unclear. We aimed to explore the effect of RDN on cardiac remodelling in rats exposed to CIH and to discuss the underlying mechanisms. Adult Sprague Dawley rats were divided into four groups: control, control+RDN, CIH (CIH exposure for 6 weeks, nadir of 5%-7% to peak of 21% O2, 20 cycles/h, 8 h/day) and CIH+ RDN group. Echocardiog...
Source: Clinical and Experimental Pharmacology and Physiology - June 13, 2023 Category: Drugs & Pharmacology Authors: Dasheng Lu Kai Wang Wanying Jiang Hao Zhang Hongxiang Zhang Source Type: research

Effect of renal denervation on cardiac remodelling and function in rats with chronic intermittent hypoxia
Clin Exp Pharmacol Physiol. 2023 Jun 13. doi: 10.1111/1440-1681.13797. Online ahead of print.ABSTRACTChronic intermittent hypoxia (CIH) mimicking obstructive sleep apnea elicits divergent outcomes in the cardiovascular systems. The effect of renal denervation (RDN) on the heart during CIH remains unclear. We aimed to explore the effect of RDN on cardiac remodelling in rats exposed to CIH and to discuss the underlying mechanisms. Adult Sprague Dawley rats were divided into four groups: control, control+RDN, CIH (CIH exposure for 6 weeks, nadir of 5%-7% to peak of 21% O2, 20 cycles/h, 8 h/day) and CIH+ RDN group. Echocardiog...
Source: Clinical and Experimental Pharmacology and Physiology - June 13, 2023 Category: Drugs & Pharmacology Authors: Dasheng Lu Kai Wang Wanying Jiang Hao Zhang Hongxiang Zhang Source Type: research

Mechanism of ligusticum cycloprolactam against neuroinflammation based on network pharmacology and experimental verification
In this study, we combined network pharmacological methods with experimental verification to investigate the anti-neuroinflammatory effects and mechanisms of ligustilide and LIGc. Based on our network pharmacology analysis, we identified four key targets of ligustilide involved in exerting an anti-inflammatory effect, with the nuclear factor (NF)-κB signal pathway suggested as the main signalling pathway. To verify these results, we examined the expression of inflammatory cytokines and inflammation-related proteins, analysed the phosphorylation level of NF-κB, inhibitor of κBα (IκBα) and inhibitor of κB kinase α an...
Source: Clinical and Experimental Pharmacology and Physiology - June 12, 2023 Category: Drugs & Pharmacology Authors: Juan Gao Gang Su Wei Chen Qionghui Wu Junxi Liu Jifei Liu Miao Chai Ying Dong He Wang Lixia Chen Zhenchang Zhang Manxia Wang Source Type: research

Geldanamycin ameliorates multiple organ dysfunction and microthrombosis in septic mice by inhibiting the formation of the neutrophil extracellular network by activating heat shock factor 1 HSF1
In conclusion, our study elucidated the protective effects of GA in a mouse model established using CLP, and the results reveal that GA may be a promising agent for sepsis.PMID:37308449 | DOI:10.1111/1440-1681.13798 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - June 12, 2023 Category: Drugs & Pharmacology Authors: Jing Li Ruijing Xuan Weidong Wu Hailong Zhang Jie Zhao Shan Zhang Source Type: research

Mechanism of ligusticum cycloprolactam against neuroinflammation based on network pharmacology and experimental verification
In this study, we combined network pharmacological methods with experimental verification to investigate the anti-neuroinflammatory effects and mechanisms of ligustilide and LIGc. Based on our network pharmacology analysis, we identified four key targets of ligustilide involved in exerting an anti-inflammatory effect, with the nuclear factor (NF)-κB signal pathway suggested as the main signalling pathway. To verify these results, we examined the expression of inflammatory cytokines and inflammation-related proteins, analysed the phosphorylation level of NF-κB, inhibitor of κBα (IκBα) and inhibitor of κB kinase α an...
Source: Clinical and Experimental Pharmacology and Physiology - June 12, 2023 Category: Drugs & Pharmacology Authors: Juan Gao Gang Su Wei Chen Qionghui Wu Junxi Liu Jifei Liu Miao Chai Ying Dong He Wang Lixia Chen Zhenchang Zhang Manxia Wang Source Type: research

Geldanamycin ameliorates multiple organ dysfunction and microthrombosis in septic mice by inhibiting the formation of the neutrophil extracellular network by activating heat shock factor 1 HSF1
In conclusion, our study elucidated the protective effects of GA in a mouse model established using CLP, and the results reveal that GA may be a promising agent for sepsis.PMID:37308449 | DOI:10.1111/1440-1681.13798 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - June 12, 2023 Category: Drugs & Pharmacology Authors: Jing Li Ruijing Xuan Weidong Wu Hailong Zhang Jie Zhao Shan Zhang Source Type: research